Key Developments: Prima BioMed Ltd (PRR.AX)

PRR.AX on Australia Stock Exchange

25 May 2015
Change (% chg)

$0.03 (+31.87%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Prima BioMed Ltd announces issue of shares
3:19am EDT 

Prima BioMed Ltd:Issues that 185,907,263 ordinary shares.  Full Article

Prima BioMed Ltd to commercialise CVAC'S database management platform with Database Integrations Inc
Sunday, 24 May 2015 07:45pm EDT 

Prima BioMed Ltd:SAYS that it has reached agreement with US-based Database Integrations Inc. (DBI) for two companies to commercialise iCAN, the software platform that powers Prima's CVac cellular therapy, for use in other cellular therapies worldwide.  Full Article

Prima BioMed Ltd announces A$15 million investment from US healthcare investor ridgeback
Wednesday, 13 May 2015 09:26pm EDT 

Prima BioMed Ltd:Enters into agreement with Ridgeback Capital Investments for Ridgeback to invest A$15 million in Prima.Says Ridgeback is a US-based specialist healthcare investor run by Wayne Holman, who is widely regarded as one of world's pre-eminent biotech investors.  Full Article

Prima BioMed Ltd announces collaboration with NEC Corp and Yamaguchi University
Sunday, 10 May 2015 08:14pm EDT 

Prima BioMed Ltd:Announces collaboration with NEC Corporation and Yamaguchi University for Immutep's IMP321 in combination with peptide vaccine developed by NEC and Yamaguchi University.Preclinical study, to be conducted at Yamaguchi University and supported by NEC, will investigate use of antigen presenting cell activator IMP321 as an adjuvant, together with peptide antigens believed to be involved in hepatocellular cancer.  Full Article

Prima BioMed Ltd's IMP321 patent application receives canadian patent office notice of grant
Sunday, 21 Dec 2014 09:00pm EST 

Prima BioMed Ltd:Says that it has received a Notice of Grant from the Canadian Patent Office for Patent application CA 2,732,570 entitled, Use of MHC class II Ligands as Adjuvants for Vaccination and of LAG-3 in Cancer Treatment.  Full Article

Prima BioMed Ltd completes acquisition of Immutep SA
Tuesday, 16 Dec 2014 09:00pm EST 

Prima BioMed Ltd:Announces acquisition of Immutep SA, the French privately owned biopharmaceutical company in the rapidly growing field of Immuno-Oncology has been completed.Prima has made an upfront cash payment of $10.8 million with the remaining cash component of $7.2 million partly payable on the achievement of a predetermined milestone and partly payable after 12 months subject to the satisfaction of warranty retention arrangements.Prima has also issued $3 million worth of Prima ordinary shares, which are subject to trading limitations, to Immutep shareholders at a price of A$0.04016 per share.Issued up to 200 million warrants which expire after four years.The total consideration paid by Prima for the acquisition is estimated to be about $25 million as opposed to the previously estimated $28 million.  Full Article

Prima BioMed Ltd initiates pancreatic clinical trial with CVAC
Sunday, 14 Dec 2014 07:00pm EST 

Prima BioMed Ltd:Says that it has received the necessary regulatory approvals for the commencement of a single-arm, pilot trial for CVac in pancreatic cancer patients in remission, protocol number CAN- 301.Says it has received regulatory allowance and ethical approval in Bulgaria, Poland and Germany.  Full Article

Prima BioMed Ltd announces investment agreement for up to $37.4 mln to fund acquisition of Immutep SA and provide ongoing working capital
Wednesday, 1 Oct 2014 07:49pm EDT 

Prima BioMed Ltd:Announces execution of investment agreement with Bergen Global Opportunity Fund, LP, a New York institutional investor managed by Bergen Asset Management, LLC.Under agreement, Bergen will make initial upfront investment of $2.5 million by way of 36-month interest-free unsecured convertible security.Bergen will also invest up to $700,000 per month in Prima's equity over next 24 months, with option to increase each of monthly tranches to amount not exceeding $1.5 million by mutual consent of Bergen and the company.  Full Article

Prima BioMed Ltd announces proposed acquisition of Immutep SA
Wednesday, 1 Oct 2014 07:42pm EDT 

Prima BioMed Ltd:Reaches agreement to acquire Immutep SA,a late stage privately owned biopharmaceutical company in rapidly growing field of immuno-oncology.Says that it will pay consideration of up to about $28 mln through combination of cash, shares and warrants subject to the achievement of certain performance milestones.Transaction is to be funded via an investment agreement with Bergen Global Opportunity Fund, LP.  Full Article

Prima Biomed Ltd receives US patent grant for CVAC
Tuesday, 15 Jul 2014 09:00pm EDT 

Prima Biomed Ltd:Says that the US patent number 8,771,701 titled "compositions for immunotherapy and uses thereof”, which protects the company’s CVac technology, has been granted by the United States Patent and Trademark Office.Prima has also received a patent term adjustment of 1,409 days for US 8,771,701, extending the patent expiry date for the US market to Aug. 2022.  Full Article

Search Stocks